Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020
IL-19 as putative biomarker for chronic rhinosinusitis with nasal polyps Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020
Increased expression of IL-19 in metaplastic epithelium of patients with chronic rhinosinusitis and nasal polyps Source: Annual Congress 2011 - Epithelial cell biology Year: 2011
Incidence of nasal polyposis and its association with the development of chronic bronchitis and/or emphysema Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP) Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
MUC4 overexpression correlates corticoid resistance in chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Expression of cholinergic system components in the airway epithelium of COPD patients Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008
Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Mechanisms responsible for glucocorticoid insensitivity in nasal mucosa and nasal polyps Source: Annual Congress 2010 - COPD and asthma: models and human studies Year: 2010
Whole-transcriptome sequencing reveals heightened inflammation and defective host defence responses in chronic rhinosinusitis with nasal polyps Source: Eur Respir J, 54 (5) 1900732; 10.1183/13993003.00732-2019 Year: 2019
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Treatment of chronic rhinosinusitis and its effects on asthma Source: Eur Respir J 2006; 28: 68-74 Year: 2006
Immune status in patients with bronchial asthma exacerbation and comorbide digestive system diseases Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011
Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Pathophysiology of airway hyperresponsiveness in patients with nasal polyposis Source: Annual Congress 2011 - Phenotyping airway diseases Year: 2011
Functional activities of blood phagocytes in polypous rhinosinusitis Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
Reduced epithelial expression of secretory component and immunoglobulin-A deficiency in the bronchial mucosa in chronic bronchitis: role of tobacco? Source: Eur Respir J 2001; 18: Suppl. 33, 520s Year: 2001